We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
J&J's billion dollar punt on anti-amyloid antibody.
- Authors
Sheridan, Cormac
- Abstract
This article discusses a deal entered by Johnson & Johnson with Elan in 2009 to provide the latest validation of bapineuzumab's commercial potential in Alzheimer's disease. The deal not only highlights the flagship program targeting beta amyloid, but also address the financial challenge facing Elan. A company will manage the bapineuzumab development program. The drug failed to demonstrate statistically significant efficacy in a phase 2 trial. However, Ian Sanderson, analyst at Cowen, provides the drug a 50 percent likelihood of reaching the market.
- Subjects
CLINICAL drug trials; JOHNSON &; Johnson (Company); ELAN Corp. PLC; DRUG efficacy; DRUG development; SANDERSON, Ian
- Publication
Nature Biotechnology, 2009, Vol 27, Issue 8, p679
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0809-679